All news

Betting On Drug Sales: Is Viatris Or Lilly The Better Way In?

Alpha Vantage · Trefis · · AI-summarised by FinFlash

Viatris (VTRS) and Eli Lilly both recently raised their 2026 sales forecasts, though Lilly's increase was significantly larger, driven by strong performance from Mounjaro and Zepbound. While Lilly exhibits superior growth, operating margins, and lower debt, Viatris offers a lower price-to-sales ratio and is betting on its pipeline drugs, selatogrel and cenerimod, to drive future growth.

Read original source

VTRS company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.